S&P 500   3,914.46 (+2.71%)
DOW   31,667.09 (+2.38%)
QQQ   323.07 (+2.84%)
AAPL   126.99 (+4.73%)
MSFT   236.73 (+1.87%)
FB   265.52 (+3.07%)
GOOGL   2,070.64 (+2.41%)
TSLA   711.78 (+5.37%)
AMZN   3,134.85 (+1.36%)
NVDA   548.51 (-0.01%)
BABA   241.78 (+1.69%)
CGC   34.63 (+5.74%)
GE   13.27 (+5.82%)
MU   94.39 (+3.12%)
NIO   49.90 (+9.00%)
AMD   86.06 (+1.83%)
T   28.29 (+1.43%)
F   12.01 (+2.65%)
ACB   11.14 (+5.89%)
DIS   195.84 (+3.60%)
BA   224.95 (+6.10%)
NFLX   547.72 (+1.65%)
BAC   35.99 (+3.69%)
S&P 500   3,914.46 (+2.71%)
DOW   31,667.09 (+2.38%)
QQQ   323.07 (+2.84%)
AAPL   126.99 (+4.73%)
MSFT   236.73 (+1.87%)
FB   265.52 (+3.07%)
GOOGL   2,070.64 (+2.41%)
TSLA   711.78 (+5.37%)
AMZN   3,134.85 (+1.36%)
NVDA   548.51 (-0.01%)
BABA   241.78 (+1.69%)
CGC   34.63 (+5.74%)
GE   13.27 (+5.82%)
MU   94.39 (+3.12%)
NIO   49.90 (+9.00%)
AMD   86.06 (+1.83%)
T   28.29 (+1.43%)
F   12.01 (+2.65%)
ACB   11.14 (+5.89%)
DIS   195.84 (+3.60%)
BA   224.95 (+6.10%)
NFLX   547.72 (+1.65%)
BAC   35.99 (+3.69%)
S&P 500   3,914.46 (+2.71%)
DOW   31,667.09 (+2.38%)
QQQ   323.07 (+2.84%)
AAPL   126.99 (+4.73%)
MSFT   236.73 (+1.87%)
FB   265.52 (+3.07%)
GOOGL   2,070.64 (+2.41%)
TSLA   711.78 (+5.37%)
AMZN   3,134.85 (+1.36%)
NVDA   548.51 (-0.01%)
BABA   241.78 (+1.69%)
CGC   34.63 (+5.74%)
GE   13.27 (+5.82%)
MU   94.39 (+3.12%)
NIO   49.90 (+9.00%)
AMD   86.06 (+1.83%)
T   28.29 (+1.43%)
F   12.01 (+2.65%)
ACB   11.14 (+5.89%)
DIS   195.84 (+3.60%)
BA   224.95 (+6.10%)
NFLX   547.72 (+1.65%)
BAC   35.99 (+3.69%)
S&P 500   3,914.46 (+2.71%)
DOW   31,667.09 (+2.38%)
QQQ   323.07 (+2.84%)
AAPL   126.99 (+4.73%)
MSFT   236.73 (+1.87%)
FB   265.52 (+3.07%)
GOOGL   2,070.64 (+2.41%)
TSLA   711.78 (+5.37%)
AMZN   3,134.85 (+1.36%)
NVDA   548.51 (-0.01%)
BABA   241.78 (+1.69%)
CGC   34.63 (+5.74%)
GE   13.27 (+5.82%)
MU   94.39 (+3.12%)
NIO   49.90 (+9.00%)
AMD   86.06 (+1.83%)
T   28.29 (+1.43%)
F   12.01 (+2.65%)
ACB   11.14 (+5.89%)
DIS   195.84 (+3.60%)
BA   224.95 (+6.10%)
NFLX   547.72 (+1.65%)
BAC   35.99 (+3.69%)
Log in
TSE:ONC

Oncolytics Biotech Inc. (ONC.TO) Stock Forecast, Price & News

C$4.22
+0.13 (+3.18 %)
(As of 03/1/2021 02:39 PM ET)
Add
Compare
Today's Range
C$4.12
Now: C$4.22
C$4.26
50-Day Range
C$3.07
MA: C$3.58
C$4.85
52-Week Range
C$1.35
Now: C$4.22
C$5.95
Volume188,340 shs
Average Volume302,918 shs
Market CapitalizationC$182.72 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

Headlines

Is Oncolytics Biotech, Inc. (ONCY) A Good Stock To Buy?
November 26, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-403-6707380
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.64 per share
Book ValueC$0.50 per share

Profitability

Miscellaneous

Market CapC$182.72 million
Next Earnings Date3/5/2021 (Confirmed)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.25 out of 5 stars

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
C$4.22
+0.13 (+3.18 %)
(As of 03/1/2021 02:39 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ONC News and Ratings via Email

Sign-up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Oncolytics Biotech Inc. (ONC.TO) (TSE:ONC) Frequently Asked Questions

Is Oncolytics Biotech Inc. (ONC.TO) a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech Inc. (ONC.TO) in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Oncolytics Biotech Inc. (ONC.TO) stock.
View analyst ratings for Oncolytics Biotech Inc. (ONC.TO)
or view top-rated stocks.

What stocks does MarketBeat like better than Oncolytics Biotech Inc. (ONC.TO)?

Wall Street analysts have given Oncolytics Biotech Inc. (ONC.TO) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oncolytics Biotech Inc. (ONC.TO) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Oncolytics Biotech Inc. (ONC.TO)'s next earnings date?

Oncolytics Biotech Inc. (ONC.TO) is scheduled to release its next quarterly earnings announcement on Friday, March 5th 2021.
View our earnings forecast for Oncolytics Biotech Inc. (ONC.TO)
.

How has Oncolytics Biotech Inc. (ONC.TO)'s stock price been impacted by Coronavirus (COVID-19)?

Oncolytics Biotech Inc. (ONC.TO)'s stock was trading at C$2.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ONC shares have increased by 75.9% and is now trading at C$4.17.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ONC?

3 Wall Street analysts have issued 1 year price objectives for Oncolytics Biotech Inc. (ONC.TO)'s stock. Their forecasts range from C$6.00 to C$6.00. On average, they anticipate Oncolytics Biotech Inc. (ONC.TO)'s stock price to reach C$6.00 in the next twelve months. This suggests a possible upside of 43.9% from the stock's current price.
View analysts' price targets for Oncolytics Biotech Inc. (ONC.TO)
or view top-rated stocks among Wall Street analysts.

Who are Oncolytics Biotech Inc. (ONC.TO)'s key executives?

Oncolytics Biotech Inc. (ONC.TO)'s management team includes the following people:
  • Dr. Matthew C. Coffey, Pres, CEO & Director
  • Mr. Kirk J. Look C.A., CA, Chief Financial Officer
  • Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 54, Pay $544.58k)
  • Mr. John Mark Lievonen B.B.A., F.C.A., M.B.A., CM, FCPA, FCA, LLD, Consultant
  • Dr. Thomas C. Heineman M.D., Ph.D., Global Head of Clinical Devel. & Operations
  • Jon Patton, Director of Investor Relations & Communication
  • Dr. Grey Wilkinson Ph.D., Scientist of Translational Medicine
  • Dr. Daniel Douglas Von Hoff M.D., F.A.C.P., Consultant (Age 73)

Who are some of Oncolytics Biotech Inc. (ONC.TO)'s key competitors?

What other stocks do shareholders of Oncolytics Biotech Inc. (ONC.TO) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech Inc. (ONC.TO) investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix Corp. (RVX.TO) (RVX), Ballard Power Systems (BLDP), (ECA), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy Ltd. (BIR.TO) (BIR), Enbridge (ENB) and First Majestic Silver Corp. (FR.TO) (FR).

What is Oncolytics Biotech Inc. (ONC.TO)'s stock symbol?

Oncolytics Biotech Inc. (ONC.TO) trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."

How do I buy shares of Oncolytics Biotech Inc. (ONC.TO)?

Shares of ONC and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Oncolytics Biotech Inc. (ONC.TO)'s stock price today?

One share of ONC stock can currently be purchased for approximately C$4.17.

How much money does Oncolytics Biotech Inc. (ONC.TO) make?

Oncolytics Biotech Inc. (ONC.TO) has a market capitalization of C$180.56 million.

What is Oncolytics Biotech Inc. (ONC.TO)'s official website?

The official website for Oncolytics Biotech Inc. (ONC.TO) is www.oncolyticsbiotech.com.

Where are Oncolytics Biotech Inc. (ONC.TO)'s headquarters?

Oncolytics Biotech Inc. (ONC.TO) is headquartered at 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada.

How can I contact Oncolytics Biotech Inc. (ONC.TO)?

Oncolytics Biotech Inc. (ONC.TO)'s mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380.


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.